In my opinion the inflection point for Cardiex was back in April 2020 when the successful trial with Blumio and Macquarie University was announced.
The company said :
”“The ability to remotely monitor heart and cardiovascular health using a wearable is fundamental to maintaining global population health in the ensuing post-COVID world,” CardieX stated.
They were announcing that they now had the ability to sell directly to billions of consumers, not thousands of customers ( hospitals and clinics ). The fuse had been lit, but as to what finally causes the tipping point 9 months later. Who knows ?
I do know that the genie is now out of the bottle. Investors seeing sustained growth doing research on CDX this week will realise this is just the beginning.
Very pleased to be a SH right now. IMO.
Add to My Watchlist
What is My Watchlist?
